Diabetic kidney disease (DKD) leads to complications that include end-stage renal disease (ESRD), cardiovascular disease, infection, and death. For the first time in decades, the FDA approved the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin for the treatment of DKD in patients with type 2 diabetes (T2D). Additionally, accumulating data from the SGLT2 inhibitor class are informing clinicians on the need to individualize treatment. This online curriculum will provide expert perspectives from nephrologists, endocrinologists, primary care providers (PCPs), and cardiologists on the increasing role of SGLT2 inhibitors beyond glucose control.
Supported by an independent educational grant from
Janssen Pharmaceuticals, Inc.
Developed through a collaboration between the University of Chicago Medicine and Medscape Education.
Steering Committee Chair
Professor of Medicine
Director
AHA Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois, United States
Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana, United States
The Frist Clinic
Nashville, Tennessee, United States
Clinical Professor of Medicine
University of California at San Diego
San Diego, California, United States
Scientia Professor of Medicine
George Institute
UNSW Sydney
Sydney, Australia
Clinical Professor of Medicine
University of Washington
Spokane, Washington, United States